On Saturday afternoon, we are going to be running two sessions in parallel - one about Lorlatinib and the other about Alectiinib and Brigatinib. Both sessions will cover managing side-effects, including dose reductions and pauses in treatment, and the options on progression.

Delegates can choose which session that they wish to attend but we would like to know how many are likely to attend each session.

Could you please complete this short questionnaire.

Many thanks,

Conference Team

1.Name

2.I am

a patient

a carer

neither

3.The patient is currently taking

Crizotinib

Ceritinib

Alectinib

Brigatinib

Lorlatinib

Neladalkib

None of the above

Don't know

4.I would like to attend the

Alectinib/Brigatinib session

Lorlatinib session

I will not be attending either session

5.Thank you. Is there anything that you wish to add?